Yu Chunfeng, Jiang Zhonghua, Hou Aihua, Mu Yuejun, Liu Wei, Tan Song
Department of Oncology Department of Image, Yantai Hospital of Traditional Chinese Medicine, Yantai, China.
Medicine (Baltimore). 2017 May;96(19):e6818. doi: 10.1097/MD.0000000000006818.
The aim of this study was to evaluate effects of Shen-Cao granules for the prevention of thrombocytopenia caused by anticancer chemotherapy.
In this prospective study, a total of 200 patients with various malignant tumors were enrolled and evenly divided into a Shen-Cao granule treatment (n = 100) and a control group (n = 100). After 2 cycles chemotherapy with any combination of platinum-based drugs (cisplatin, carboplatin, and nedaplatin), the blood platelet (PLT) counts, levels of the PLT production regulator thrombopoietin (TPO), PLT aggregation rates, and the PLT activation marker CD62P expressions were monitored for 2 weeks.
During 2 weeks of post-chemotherapy, the mean values of the minimum PLT count were 49.65 ± 7.35 × 10/L in the treatment group and 31.56 ± 9.32 × 10/L in the control group. The PLT count in the treatment group reached the lowest value 1.8 days later and recovered to a concentration ≥100 × 10/L 3 days earlier than in the control group. The concentrations of the TPO were 71.43 ± 1.74 and 87.24 ± 0.92 ng/mL in the treatment group and 65.75 ± 1.39 and 67.75 ± 0.67 ng/mL in the control group at 7 and 14 days post-chemotherapy, respectively. The maximum PLT aggregation rate declined after chemotherapy in the treatment group from 58.14 ± 11.46% to 52.89 ± 10.52%, while it increased in the control group from 56.94 ± 10.55% to 61.75 ± 12.26%. Coordinately, the expression of CD62P in the treatment group decreased from 6.17 ± 0.59% to 4.89 ± 0.72%, while it increased from 6.09 ± 0.75% to 7.75 ± 0.67% in the control group.
Our study demonstrated that Shen-Cao granule treatment alleviated thrombocytopenia after chemotherapy, and reduced tumor-induced PLT activation and aggregation.
本研究旨在评估参草颗粒预防抗癌化疗所致血小板减少的效果。
在这项前瞻性研究中，共纳入200例患有各种恶性肿瘤的患者，并将其平均分为参草颗粒治疗组（n = 100）和对照组（n = 100）。在使用任何铂类药物（顺铂、卡铂和奈达铂）组合进行2个周期化疗后，监测血小板（PLT）计数、血小板生成调节因子血小板生成素（TPO）水平、血小板聚集率以及血小板活化标志物CD62P表达，为期2周。
化疗后2周内，治疗组血小板最低计数平均值为49.65±7.35×10⁹/L，对照组为31.56±9.32×10⁹/L。治疗组血小板计数在1.8天后达到最低值，比对照组提前3天恢复至≥100×10⁹/L的浓度。化疗后7天和14天，治疗组TPO浓度分别为71.43±1.74和87.24±0.92 ng/mL，对照组分别为65.75±1.39和67.75±0.67 ng/mL。治疗组化疗后最大血小板聚集率从58.14±11.46%降至52.89±10.52%，而对照组从56.94±10.55%升至61.75±12.26%。相应地，治疗组CD62P表达从6.17±0.59%降至4.89±0.72%，而对照组从6.09±0.75%升至7.75±0.67%。
我们的研究表明，参草颗粒治疗可减轻化疗后血小板减少，并降低肿瘤诱导的血小板活化和聚集。
